Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Overview
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Companies Involved in Therapeutics Development
Albireo Pharma Inc
GlaxoSmithKline Plc
Mirum Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Drug Profiles
Drug to Inhibit IBAT for Liver and Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elobixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linerixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
odevixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Dormant Products
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Discontinued Products
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: Mirum Pharmaceuticals completes successful pre-NDA meeting with FDA for Maralixibat
Nov 08, 2019: Mirum Pharmaceuticals presents data demonstrating long-term durability of treatment effect of Maralixibat in children with cholestatic liver diseases
Oct 28, 2019: Mirum Pharmaceuticals announces Breakthrough Therapy Desigtion for Maralixibat for the treatment of pruritus associated with Alagille syndrome
Oct 21, 2019: Durability of treatment effect of Mirum Pharmaceuticals Maralixibat for children with Alagille syndrome featured in late breaking session at the Liver Meeting 2019
Oct 01, 2019: Mirum Pharmaceuticals to present new data on Volixibat Potassium at The Liver Meeting 2019
Oct 01, 2019: Mirum Pharmaceuticals to present new data on Maralixibat Chloride at The Liver Meeting 2019
Sep 30, 2019: Albireo announces presentations at SPGHAN 2019 Annual Meeting
Jul 09, 2019: Albireo provides clinical development update on elobixibat
Jul 09, 2019: Albireo provides clinical development update for odevixibat
Jul 09, 2019: Mirum Pharmaceuticals initiates phase 3 clinical trial for pediatric patients with progressive familial intrahepatic cholestasis
Jun 07, 2019: Data on Albireo’s odevixibat presented at 2019 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
May 23, 2019: Albireo Announces Data on Pediatric Cholestatic Liver Diseases to be Presented at the 2019 ESPGHAN Annual Meeting
Apr 15, 2019: Albireo to assess elobixibat in Phase II trial for liver diseases
Apr 15, 2019: Mirum Pharmaceuticals presented data on Volixibat at The Intertiol Liver Congress 2019
Apr 15, 2019: Mirum Pharmaceuticals presented new data demonstrating durable improvements in clinical outcome measures in patients with PFIC2 and Alagille syndrome treated with Maralixibat
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Albireo Pharma Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Mirum Pharmaceuticals Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019